FDA Legislative Proposals Would Modernize and Streamline Regulatory Process for Promising Medical Products

FDA Legislative Proposals Would Modernize and Streamline Regulatory Process for Promising Medical Products 

The FDA’s regulatory review process is not optimized for the speed and innovation of modern biotechnology. Friction in this system leads to delays in getting products to market which can stall review and stifle industry growth.

7 April 2026

 

FOR IMMEDIATE RELEASE

Washington, DC – The National Security Commission on Emerging Biotechnology (NSCEB) welcomes the Food and Drug Administration’s (FDA) proposed reforms for modernizing U.S. clinical trials for innovative medical products and for prioritizing supply chain security for critical medical products.

 

A year ago, the NSCEB published 49 recommendations in its Action Plan for American biotechnology and national security, including recommendations on streamlining the regulatory system and requiring the disclosure of supply chain vulnerabilities for critical materials. This January, the NSCEB published new analysis and 83 policy options to modernize and accelerate U.S. regulatory review of biotechnology products across the federal government, including policy options for modernizing medical biotechnology regulation. Many of the proposals in FDA’s budget align with NSCEB recommendations.

 

An outdated regulatory system creates unnecessary burdens and slows or prevents promising new biotechnology products from coming to market. A more efficient process will unleash U.S. biotechnology innovation and support economic growth and national security.  

 

By contrast, China’s overhaul of its clinical trial and drug regulatory system is central to its strategy to outpace the U.S. in biopharmaceutical innovation. Through targeted reforms to the nation’s clinical trial processes, China has enabled biopharmaceutical companies to conduct faster and cheaper early-stage clinical trials. This, in turn, allows startups that perform their trials in China to obtain a strategic advantage over competing forms by reaching proof-of-concept earlier and thereby attract investor interest to scale and out-license other drugs. est to scale and out-license other drugs.

 

The FDA’s FY2027 budget proposal includes legislative proposals that would:

• “Create a new Clinical Trial Notification Pathway to Serve as an Alternative to the Burdensome Existing Investigational New Drug Pathway to accelerate drug development timeline to Make America Healthy Again”
  
  • The NSCEB has highlighted that there are currently barriers to speedy initiation of phase I clinical trials, especially in the Investigational New Drug (IND) submission.
  • The NSCEB also found that by validating more modern testing methods such as NAMs, the FDA could further reduce barriers to entry for drug developers working on innovative medical products. 

• “Allow Disclosure of Certain Information in Complete Response Letters” 
  
  • NSCEB urged Congress to direct that the FDA should help developers meet data expectations by releasing aggregated, de-identified reports of common deficiencies from Complete Response Letters (CRLs).

• “Give FDA significant enforcement authorities, including civil monetary penalties and the authority to pull products off of market if API source data is not reported” 
  
  • In its April 2025 Action Plan, the NSCEB found that supply chain vulnerabilities in countries of concern is a major national security issue that poses significant risk to economic resilience and supply chain security for critical materials.
  • The NSCEB also called for the FDA to work with other agencies to coordinate enforcement of country-of-origin labeling requirements for medical products.

Learn more about the NSCEB’s policy options for creating clear regulatory pathways for biotechnology here, and read the policy options specifically for medical biotechnology products here.

 

About NSCEB: The National Security Commission on Emerging Biotechnology is a time-limited, high-impact legislative branch advisory entity whose purpose is to advance and secure biotechnology, biomanufacturing, and associated technologies for U.S. national security and to prepare the United States for the bioindustrial revolution. The Commission published a comprehensive report in April 2025, including recommendations for action by Congress and the federal government. The bipartisan Commission is composed of Congressionally-appointed Commissioners with members from both the Senate and the House of Representatives as well as experts from industry, academia, and government. For more information about the Commission and to view the report, visit: biotech.senate.gov.

Contacts:

 

NSCEB: press@biotech.senate.gov